化瘀止崩汤治疗气滞血瘀型崩漏患者的效果及安全性分析

Analysis of the Efficacy and Safety of Huayu Zhibeng Decoction in Treating Patients with Metrorrhagia Due to Qi Stagnation and Blood Stasis

摘要: 目的：观察和分析化瘀止崩汤治疗气滞血瘀型崩漏患者的作用机制。方法：分析我院收治的80例气滞血瘀型崩漏患者，分为对照组和观察组，每组40例，对照组患者给予常规西药治疗，观察组对照组治疗基础上予以化瘀止崩汤加减治疗，连续干预3个月经周期。比较两组患者的治疗前后中医症候评分、出血控制情况、临床有效率、用药安全性。结果：观察组患者治疗后的中医症候评分(经量异常、无规律经血、经血色质暗紫伴血块、下腹部疼痛)低于对照组，差异具有统计学意义(P < 0.05)。观察组临床有效率为优于对照组(95% > 82.5%)，差异具有统计学意义(P < 0.05)。观察组的出血控制、完全止血时间以及用药安全性均优于对照组，差异具有统计学意义(P < 0.05)。结论：化瘀止崩汤加减治疗气滞血瘀型崩漏临床效果显著，且安全性高，值得临床推广。

Abstract: Objective: To observe and analyze the mechanism of Huayu Zhibeng Decoction in treating patients with metrorrhagia due to qi stagnation and blood stasis. Method: We analyzed 80 patients with metrorrhagia of qi stagnation and blood stasis type treated in our hospital, who were divided into a control group and an observation group, with 40 patients in each group. The control group received conventional western medicine treatment, while the observation group was treated with Huayu Zhibeng Decoction in addition to the control group’s treatment, for three consecutive menstrual cycles. We compared the TCM symptom scores, bleeding control, clinical effectiveness rate, and medication safety between the two groups before and after treatment. Results: After treatment, the TCM symptom scores in the observation group (abnormal menstrual volume, irregular menses, dark-purple menstrual blood with clots, lower-abdominal pain) were significantly lower than those in the control group (P < 0.05). The clinical effective rate was also superior in the observation group (95% vs 82.5%), and the difference was statistically significant (P < 0.05). The bleeding control, complete hemostasis time, and medication safety in the observation group were better than those in the control group, with a statistically significant difference (P < 0.05). Conclusion: The modified Huayu Zhibeng Decoction demonstrates significant clinical efficacy and high safety in treating metrorrhagia due to qi stagnation and blood stasis, and is worthy of clinical promotion.